Last reviewed · How we verify

NCT06628791

BK329 and Body Fat Reduction

Completed NA Last updated 6 January 2026
What this trial tests

NA trial testing BK329 in Obesity and Overweight in 100 participants. Completed in 31 December 2024.

Timeline
26 January 2024
Primary endpoint
8 July 2024
31 December 2024

Quick facts

Lead sponsorPusan National University Yangsan Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment100
Start date26 January 2024
Primary completion8 July 2024
Estimated completion31 December 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Pusan National University Yangsan Hospital

Who can join

Adults 19 to 75, any sex, with Obesity and Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial aims to determine whether BK329 reduces body fat in adults with overweight or obesity and to assess its safety. The main questions are: * Does BK329 reduce body fat in participants? * What side effects occur when participants take BK329?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity and Overweight

Currently open trials in the same condition.

Other Pusan National University Yangsan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06628791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing